| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
71,917,000 |
| Market
Cap: |
6.45(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$35.09 - $90.07 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 446 |
| Guru Rank Value : 4.5 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Protagonist Therapeutics is a clinical-stage biopharmaceutical company with various peptide-based new chemical entities in different stages of development, all derived from Co.'s proprietary technology platform. Co.'s clinical programs address two main categories of diseases; hematology and blood disorders, and inflammatory and immunomodulatory diseases. Co.'s main clinical asset, rusfertide (generic name for PTG-300) is an injectable hepcidin mimetic in development for the potential treatment of erythrocytosis, iron overload and other blood disorders. PN-943 is an investigational, orally delivered, gut-restricted alpha-4-beta-7 specific integrin antagonist for inflammatory bowel disease.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
18,712 |
105,571 |
124,244 |
626,906 |
| Total Sell Value |
$1,466,376 |
$6,279,354 |
$6,781,737 |
$25,903,287 |
| Total People Sold |
2 |
3 |
4 |
5 |
| Total Sell Transactions |
3 |
10 |
15 |
35 |
| End Date |
2025-09-07 |
2025-06-06 |
2024-12-06 |
2023-12-07 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
Patel Dinesh V Ph D |
President and CEO |
|
2025-11-21 |
4 |
GD |
$0.00 |
$0 |
D/D |
440 |
519,543 |
|
- |
|
Molina Arturo Md |
Chief Medical Officer |
|
2025-11-17 |
4 |
S |
$84.77 |
$229,896 |
D/D |
(2,712) |
81,180 |
|
-3% |
|
Waddill William D. |
Director |
|
2025-10-10 |
4 |
AS |
$69.25 |
$979,480 |
D/D |
(12,000) |
5,130 |
|
3% |
|
Waddill William D. |
Director |
|
2025-10-10 |
4 |
OE |
$6.98 |
$83,760 |
D/D |
12,000 |
17,130 |
|
- |
|
Waddill William D. |
Director |
|
2025-09-22 |
4 |
AS |
$64.25 |
$257,000 |
D/D |
(4,000) |
5,130 |
|
39% |
|
Patel Dinesh V Ph D |
President and CEO |
|
2025-09-16 |
4 |
GD |
$0.00 |
$0 |
D/D |
620 |
519,983 |
|
- |
|
Waddill William D. |
Director |
|
2025-08-27 |
4 |
AS |
$59.25 |
$237,000 |
D/D |
(4,000) |
9,130 |
|
46% |
|
Patel Dinesh V Ph D |
President and CEO |
|
2025-07-25 |
4 |
S |
$54.78 |
$570,534 |
D/D |
(10,415) |
520,603 |
|
-53% |
|
Patel Dinesh V Ph D |
President and CEO |
|
2025-07-23 |
4 |
S |
$54.79 |
$959,921 |
D/D |
(17,520) |
531,018 |
|
-66% |
|
Patel Dinesh V Ph D |
President and CEO |
|
2025-07-22 |
4 |
S |
$55.05 |
$1,214,678 |
D/D |
(22,065) |
548,538 |
|
-64% |
|
Patel Dinesh V Ph D |
President and CEO |
|
2025-07-21 |
4 |
S |
$54.86 |
$705,445 |
D/D |
(12,859) |
570,603 |
|
-63% |
|
Patel Dinesh V Ph D |
President and CEO |
|
2025-07-21 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
583,462 |
|
- |
|
Patel Dinesh V Ph D |
President and CEO |
|
2025-07-16 |
4 |
GD |
$0.00 |
$0 |
D/D |
5,000 |
558,462 |
|
- |
|
Patel Dinesh V Ph D |
President and CEO |
|
2025-06-16 |
4 |
GD |
$0.00 |
$0 |
D/D |
685 |
562,905 |
|
- |
|
Patel Dinesh V Ph D |
President and CEO |
|
2025-06-13 |
4 |
GD |
$0.00 |
$0 |
D/D |
670 |
563,590 |
|
- |
|
Molina Arturo Md |
Chief Medical Officer |
|
2025-06-10 |
4 |
S |
$57.03 |
$570,300 |
D/D |
(10,000) |
83,892 |
|
-37% |
|
Molina Arturo Md |
Chief Medical Officer |
|
2025-06-10 |
4 |
OE |
$8.04 |
$80,400 |
D/D |
10,000 |
93,892 |
|
- |
|
Molina Arturo Md |
Chief Medical Officer |
|
2025-06-09 |
4 |
S |
$55.51 |
$555,100 |
D/D |
(10,000) |
83,892 |
|
-36% |
|
Molina Arturo Md |
Chief Medical Officer |
|
2025-06-09 |
4 |
OE |
$8.04 |
$80,400 |
D/D |
10,000 |
93,892 |
|
- |
|
Selick Harold E |
Director |
|
2025-04-28 |
4 |
OE |
$1.16 |
$12,441 |
D/D |
10,725 |
43,851 |
|
- |
|
Ali Asif |
Chief Financial Officer |
|
2025-04-22 |
4 |
S |
$46.00 |
$80,776 |
D/D |
(1,756) |
61,065 |
|
-29% |
|
Waddill William D. |
Director |
|
2025-03-17 |
4 |
AS |
$54.25 |
$217,000 |
D/D |
(4,000) |
13,130 |
|
4% |
|
Patel Dinesh V Ph D |
President and CEO |
|
2025-03-05 |
4 |
OE |
$4.21 |
$101,040 |
D/D |
24,000 |
564,260 |
|
- |
|
Patel Dinesh V Ph D |
President and CEO |
|
2025-02-19 |
4 |
S |
$38.18 |
$204,607 |
D/D |
(5,359) |
540,260 |
|
-43% |
|
Molina Arturo Md |
Chief Medical Officer |
|
2025-01-16 |
4 |
S |
$0.00 |
$0 |
D/D |
(3,640) |
83,892 |
|
-25% |
|
225 Records found
|
|
Page 1 of 9 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|